Wipro Working with AWS To Transform Lab Processes in the Life Sciences Industry

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, announced that it is working with Amazon Web Services (AWS) to redefine the future of lab processes in the life sciences industry. 

The life science and pharmaceutical industries have long struggled with outdated laboratory processes that hinder efficiency and increase costs. Lab technicians, lab associates, and medical specialists often find themselves performing tasks outside of their expertise due to the fragmentation of laboratory operations across various platforms. This lack of cohesion not only results in inefficiencies but also extends the time required to bring new drugs and products to market, subsequently increasing research and development expenses.

Recognizing these challenges, Wipro began working with AWS to create the Lab of the Future. This innovative solution addresses the root issues that have plagued the industry, offering a comprehensive, cloud-based platform that streamlines laboratory processes and enhances collaboration among stakeholders.

Our vision with launching Lab of the Future, is to deliver holistic lab performance powered by generative AI, advanced analytics, and a consultative business first approach,” said Philippe Dintrans, Senior Vice President & Global Head of Domain & Consulting at Wipro Consulting.

Among the key challenges facing the Life Sciences industry today are decreasing ROI for R&D (R&D returns fell to 1.8% in 2019, down from 10% in 20101), increasing cost of bringing new drugs to the market, and the significant amount of time spent on data management, which takes 45% of data scientists’ time, according to recent surveys.2

By introducing the Lab of the Future, Wipro and AWS aim to empower the life sciences industry with a modern, efficient, and collaborative laboratory solution that has the potential to significantly reduce costs and accelerate the development of life-saving drugs and products.

Among 12 leading large-cap biopharma companies, R&D returns fell to 1.8% in 2019—down from 10% in 2010
1https://www.us.jll.com/en/views/real-estate-as-reagent-how-the-right-life-sciences-space-can-drive-innovation
2https://www.datanami.com/2020/07/06/data-prep-still-dominates-data-scientists-time-survey-finds/


Wipro has enhanced offerings for clients across the life sciences value chain and our latest Lab innovation with AWS further illustrates our commitment to helping our clients improve business outcomes and enable cost efficiency,” said Srini Rajamani, Senior Vice President & Sector Head – Consumer and Life Sciences at Wipro.

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) is a leading technology services and consulting company focused on building innovative solutions that address clients’ most complex digital transformation needs. Leveraging our holistic portfolio of capabilities in consulting, design, engineering, and operations, we help clients realize their boldest ambitions and build future-ready, sustainable businesses. With nearly 245,000 employees and business partners across 65 countries, we deliver on the promise of helping our clients, colleagues, and communities thrive in an ever-changing world. For additional information, visit us at www.wipro.com

Advertisements

Post a Comment

أحدث أقدم
Like this content? Sign up for our daily newsletter to get latest updates.